Some patient advocate groups say the Obama administration has bargained away too much with special interest groups in order to secure promises to cut health care spending. These opponents are critical, in particular, of the $80 billion in savings pledged by leading pharmaceutical companies, which stand to gain a lot more money from more newly insured patients. Critics also point to proposals in Congress that allow 12 years of patent protection for brand-name makers of biologic drugs

Related Summaries